)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Bora Pharmaceuticals
Bora Pharmaceuticals (6472) investor relations material
Bora Pharmaceuticals 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary15 Jan, 2026
Strategic growth and global expansion
Achieved 700% market cap growth since 2017, surpassing $2 billion, through organic growth and strategic acquisitions, including Upsher-Smith, Pyros, Emergent's sterile fill and finish facility, and Tanvex, expanding U.S. and biologics capabilities.
Operates 10 manufacturing sites (5 in North America, 5 in Taiwan), exporting to 100+ countries, with 95% of revenue from outside Taiwan and a strong focus on North America.
Became the first Taiwanese company to join the U.S. OTCQX market, enhancing global visibility and investor access, with cross-market trading starting in 2026.
Re-signed multi-year commercial contracts, including a $350 million deal, and made record CapEx and sales/marketing investments in 2025.
Integrated Tanvex BioPharm as Bora Biologics, completing full-service CDMO capabilities in both small and large molecules and entering the large molecule sector.
Operational and financial performance
Fiscal 2025 revenue reached $634 million, with 3Q25 revenue at $195 million; net income from continuing operations was $129 million.
CDMO business grew 53.8% year-over-year to over $340 million, with a 96% OTIF rate and improved efficiency.
EBITDA margin rose to 40% in 2024 from 17% in 2017, with steady ROIC expansion and a focus on value creation.
Discontinued nonprofitable operations, reducing net working capital utilization from 53% to 23.69% and freeing up capital for investment.
Maintained strong cash positions, increased CapEx, paid dividends, and kept a consistent debt-to-EBITDA ratio.
Investments and capacity enhancements
Invested $400 million in U.S. CapEx over two years, focusing on organic growth, integration post-acquisition, and major investments in aseptic technologies and new filling lines across US, Canada, and Taiwan.
Maryland site received a city lab permit in Dec. 2025; cleanroom construction and validation batches scheduled for 2026.
Canadian facility increased derma product capacity by 40%, supporting a dermatology market projected to double by 2030.
New liquid-filled hard capsule capability in Taiwan to be operational in 1Q26, targeting oncology and potent drugs.
Expanded aseptic fill and finish and biologics capabilities in the U.S., with new lines and technologies coming online in 2025–2026.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Bora Pharmaceuticals earnings date
Q4 20255 Mar, 2026
Bora Pharmaceuticals
Next Bora Pharmaceuticals earnings date
Q4 20255 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Bora Pharmaceuticals Co., Ltd. is active in the pharmaceutical industry, focusing on manufacturing and selling generic, brand, and over-the-counter drugs globally. The company spans the entire pharmaceutical supply chain from research and development to sales and distribution, offering services including contract development and manufacturing, consumer healthcare & OTC, and prescription drugs. Bora's facilities are certified by USFDA, MHRA, and PIC/S, ensuring the production of pharmaceuticals to the highest medical standards for distribution to over 100 countries worldwide. The company is headquartered in Taipei City, Taiwan, and its shares are listed on the Taiwan Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage